Psychostimulants Flashcards
general drugs for ADHD
- Amphetamines/Amphetamine-like agents (methylphenidate) (IR or XR)
- Atomoxetine (NSRI)
- Guanfacine and Clonidine (alpha-2 agonists)
amphetamines MOA
(ADHD)
Monoamine agonists –> stimulate monoamine NTs (promote release of biogenic amines from storage sites)
Prevents storage of dopamine in vesicles in the axon terminal.
High levels of dopamine.
Transporters push domamine into synaptic cleft due to high concentration.
main concerns for amphetamines
(ADHD) STIMULANT EFFECTS -increased CNS (insomnia) -GI (suppressed appetite, fullness, nausea) -stimulated CV (NE release)
PSYCHOSIS
- hallucinations/delusions with high doses
- bc inc dopamine in mesolimbic path
PSYCHOLOGICAL DEPENDENCE
-Schedule II
WITHDRAWAL
- depressed mood, fatigue
- start w/ low dose and work up
Why are there cardiovascular concerns with amphetamines?
(ADHD)
Stimulants –> stimulate NE release.
NE most readily stimulates Alpha-1 receptors –> increased vasoconstriction, increased peripheral resistance –> increased BP
management of overdose of amphetamines
(ADHD)
Control cardiovascular hemodynamics
-alpha blockers, nitrates
Sedatives
-benzodiazepines
Activated Charcoal
-ties up any drug still available to prevent further absorption
Change pH of urine to much lower than pKa of drug (urine trapping since amphetamines are basic)
names of amphetamines/-like agents
(ADHD) Amphetamine (Benzedrine) -dextroamphetamine (dexedrine) -amphetamine + detroamphetamine (Adderall, most common) -lisdexfetamine (Vyvanse)
Methylphenidate (Ritalin)
- dexmethylphenidate (focalin)
- have fewer cardiovascular effects (NE effects are confined to brain)
black box label warnings for Adderall, amphetamines
- high potential for abuse
- lead to drug dependence (limbic path path stimulated)
- serious cardiovascular effects
schedule II drugs
High potential for abuse, currently accepted medical use
- restricted quantities
- highly controlled (need signature/DEA#, telephone for emergencies only, etc.)
atomoxetine (strattera) use and MOA
ADHD
Selective inhibitor of NE transport (NSRI)
NONSTIMULANT
Blocks NE reuptake so it is available in synapse for longer in prefrontal cortex.
similar mech to anti-depressants.
atomoxetine metabolism, schedule #
(ADHD) Hepatic metabolism (CYP2D6)
Schedule VI drug (non-stimulant)
atomoxetine concerns
- CNS (insomnia)
- GI (appetite suppression)
- Cardiovascular (inc bp)
- others:
- –dry mouth, urinary retention (anti-muscarinic)
- –priapism (prolonged, painful erection due to vasoconstriction)
- –drug interactions (if they block 2D6 then lead to toxicity bc inhibits clearance)
black box label warning for atomoxetine
Increased risk of suicidal ideation.
- unclear why
- confounding
- overall very small risk
Guanfacine, Clonidine use/MOA
ADHD
MOA: alpha-2 receptor agonists (sympatholytic) –> prevents release of NTs
(recall alpha-2 receptors - when stimulated - suppress release of transmitter)
(MOA for ADHD unclear)
side effects of Guanfacine, Clonidine
(ADHD)
Sedation
Dry mouth
Hypotension
what schedule # is Guanfacine and Clonidine?
(ADHD)
Schedule VI drugs
drugs for treatment of sleepiness, narcolepsy, cataplexy
Caffeine
Modafinil
Gammahydroxybutyrate
caffeine is an analog to ________
caffeine is an analog to ADENOSINE (an endogenously produced nucleoside that normally INHIBITS transmitter release)
caffeine mechanism
(sleepiness)
MOA: adenosine receptor antagonist (same shape, but does not cause same effect, just blocks site)
- ultimately inhibiting an inhibitor –> inc transmitter release
Adenosine binding to PRESYNAPTIC receptor:
- closes Ca++ channels
- decreased NT release
Adenosine binding to POSTSYNAPTIC receptor:
- open K+ channel
- hyperpolarizes cell
- decreased response to stimuli
If BLOCKED:
- increased NT release
- increased response to stimuli